Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certoparin for prevention of clotting in the extracorporeal circuit during chronic hemodialysis
2010-019200-23Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certoparin in end-stage kidney disease (ESKD), sponsored by Novartis. Primary endpoints: Unsatisfactory dialysis results at week 8 due to clotting or bleeding and Need for certoparin dose uptitration at week 8 due to clotting. Started May 2010; status: completed.
02
Drugs
certoparin
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2010-019200-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019200-23.